Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.

Evan C ChenWilliam GibsonPaula TemoczkoNathan T ConnellRobert HandinAric D Parnes

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)

Our observations suggest emicizumab can facilitate haemostasis for AHA patients and be combined with safer, lower-intensity immunosuppressive therapies to achieve remission.

Keyphrases

ejection fraction
newly diagnosed
prognostic factors
high intensity
rheumatoid arthritis
ulcerative colitis
patient reported
replacement therapy